A joint analysis of patients receiving immune checkpoint inhibitor therapy was conducted using the OnCovid (NCT04393974) and ESMO CoCARE registries, this assessed SARS-CoV-2 outcomes in vaccinated and unvaccinated patients with cancer and whether prior immune-related adverse events affected these outcomes. In this touchIMMUNOLOGY interview, we spoke with Dr Alessio Cortellini (Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy) to learn more around the aims, design and findings from the analysis.
The abstract ‘Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries‘ was presented at the ESMO Immuno-Oncology Congress, 7-9 December, 2022.
Questions
- What was known about the impact of immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer? (0:24)
- Could you give us a brief overview of the OnCovid and European Society for Medical Oncology (ESMO) CoCARE registries? (2:09)
- What were the aims and design of this analysis? (3:23)
- What were the findings in terms of immune-related adverse events and COVID-19 outcomes? (4:34)
Disclosures: Alessio Cortellini has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ESMO Immuno-Oncology Congress, 2022.
